Berotralstat (BCX7353, Orladeyo) is a novel, oral and potent kallikrein inhibitor. As of December 2020, Berotralstat was approved by FDA to prevent attacks of hereditary angioedema (HAE)

纯度：≥98%

CAS：1809010-50-1